Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers a possible a return of the blockbuster.

You may also be interested in...



Chart: "Wild Cards: NMEs and New Biologics That Are Still Pending After FDA Missed User Fee Goal Dates In 2008"

Wild Cards: NMEs and New Biologics That Are Still Pending After FDA Missed User Fee Goal Dates In 2008

Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme

In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology

Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme

In 2009, some of the biggest new drugs might not technically be drugs at all. Major biologic products could dominate the upcoming year, largely thanks to big pharma's maturing interest in biotechnology

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel